Volume 6, Issue 4 (Winter 2003)
J Arak Uni Med Sci 2003, 6(4): 46-50 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moshfeghi K, Dadgar N, Rafiee M. Laboratory and Clinical Findings in Recently Diagnosed Lymphoproliferate and Acute Leukemia Patients. J Arak Uni Med Sci 2003; 6 (4) :46-50
URL: http://jams.arakmu.ac.ir/article-1-6773-en.html
URL: http://jams.arakmu.ac.ir/article-1-6773-en.html
Laboratory and Clinical Findings in Recently Diagnosed Lymphoproliferate and Acute Leukemia Patients
Abstract: (5568 Views)
Introduction: Nearly, 6% of recently diagnosed cancer in the United States was upon to lymphoproliferate and leukemia and 9% of fatality in cancerous people was upon to these two illnesses. Using some simple, cheap and in-hand tests and special consideration to clinical inspections in suspected subjects provide a faster diagnostic and suitable treatment. It may ultimately promote the quality of life and decline the fatality among patients.
Materials and methods: This was a cross-sectional investigation which carried out during a 1.5 years in the form of forward direction. Forty-two lymphoproliferate (28 lymphoblast and 14 Hotchkin) and 21 acute lymphoblastic leukemia (10 acute lymphoblast leukemia and 11 miloid acute leukemia) subjects were evaluated. ESR, LDH and ALP levels were measured in all patients. In clinical examinations, oversizing of lymph nodes, spleen and liver were exactly considered.
Results: According to our results the best tests to rule in and rule out acute leukemia from lymphoprolifeatives were ESR and LDH, respectively. Additionally, The most sensitive and specific evaluations to rule out these two diseases were LDH and oversizing of liver inspection. It was also determined that LDH is the best screening test to rule out leukemia from lymphoproliferate.
Conclusion: Using of simple examinations such as ALP, LDH, ESR and more consideration to oversized spleen, liver and lymph nodes in each suspected patients, we could easily differentiate lymphoproliferate and acute leukemia from each other.
Materials and methods: This was a cross-sectional investigation which carried out during a 1.5 years in the form of forward direction. Forty-two lymphoproliferate (28 lymphoblast and 14 Hotchkin) and 21 acute lymphoblastic leukemia (10 acute lymphoblast leukemia and 11 miloid acute leukemia) subjects were evaluated. ESR, LDH and ALP levels were measured in all patients. In clinical examinations, oversizing of lymph nodes, spleen and liver were exactly considered.
Results: According to our results the best tests to rule in and rule out acute leukemia from lymphoprolifeatives were ESR and LDH, respectively. Additionally, The most sensitive and specific evaluations to rule out these two diseases were LDH and oversizing of liver inspection. It was also determined that LDH is the best screening test to rule out leukemia from lymphoproliferate.
Conclusion: Using of simple examinations such as ALP, LDH, ESR and more consideration to oversized spleen, liver and lymph nodes in each suspected patients, we could easily differentiate lymphoproliferate and acute leukemia from each other.
Type of Study: Original Atricle |
Subject:
Basic Sciences
Received: 2021/01/27 | Accepted: 2003/12/31
Received: 2021/01/27 | Accepted: 2003/12/31
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
